Series A · Healthtech
Graph AI raises $13.3m Series A for patient-safety platform
The company is scaling its pharmacovigilance software across the US and Europe, where pharmaceutical and biotech teams use it to process drug-safety cases.
Automating drug-safety casework with expert oversight
Graph Safety combines AI with validation controls and audit trails to help pharmaceutical and biotechnology teams handle adverse-event reports. Its Intake module captures and triages reports, while Nucleus supports case processing; Report, for aggregate reporting, was scheduled for launch in September 2026. Graph AI says live deployments have cut case-processing time from more than three hours to under 10 minutes and reduced operating costs by up to 66%.
Use of funds
Expand across the US and Europe
Accelerate product development
Funding history
Series A · This round$13.3M